Xandr Furthers Integrations with Industry IDs and Advances Proprietary Modelled and Contextual Solutions
27.10.2021 15:00:00 EEST | Business Wire | Press release
Xandr, AT&T’s advanced advertising company, today announced investments which expand its portfolio of identity offerings. Earlier this year, Xandr announced a multi-faceted approach to balance customers’ advertising needs and consumer privacy, and has now delivered several addressability solutions through integrations with LiveRamp (NYSE:Ramp), netID and Unified ID 2.0, as well as publisher first-party data activation solutions, contextual and modelled capabilities.
Facilitating addressability through consumer-consented data is a key component that Xandr has made strides on. Through Xandr’s collaboration with LiveRamp, Xandr this year launched end-to-end support for RampID on its platform. Publishers using Xandr’s Monetize SSP have started to use RampIDs in their monetization strategies and have seen positive indications. Agencies and marketers are also beginning alpha tests for RampID capabilities on Xandr’s Invest DSP, which include data onboarding, targeting and measurement. Xandr and LiveRamp are also expanding their relationship in other ways, including LiveRamp becoming a partner on Xandr Curate, the platform for monetizing data through curated deals. Travis Clinger, SVP, addressability and ecosystem at LiveRamp comments: “Our mission has always been to make it safe and easy for our partners and customers to connect data, wherever data lives. Our continued and evolving partnership with Xandr helps make that possible programmatically, bringing the demand- and sell-sides closer together to ensure critical advertising workflows are more sustainable, efficient, and performant on a global scale. Further, Xandr's support of RampID, a high-fidelity, person-level, omnichannel identifier, takes our existing integration with them to the next level.”
First-party data will be key in the new era of advertising. Xandr has laid the foundation to roll out a suite of powerful tools which empower publishers to leverage their data assets to power relevant advertising, while still protecting the privacy needs of their users. Xandr’s publisher first-party data capabilities provide the necessary targeting, frequency management and privacy controls to enable scaled monetization across environments. Today, Xandr supports netID across multiple use cases, and continues to build upon this investment, working with netID, publishers and marketers on its platform. In 2022, Xandr will launch an enhanced Publisher ID suite providing additional capabilities, which is built to address publishers’ forward-looking needs. “Providing publishers with the right tools to successfully execute business models, while ensuring that data is properly protected and users are in full control, will be of the utmost importance in this transformational shift in advertising”, says Achim Schlosser, CTO of the European netID Foundation. “First-party data is a key building block in future of digital marketing, which needs to be both user-friendly and sustainable. For that we need strong co-operation among the industry to enable a fair and open web.”
Whilst LiveRamp and netID integrations are complete, Xandr is collaborating with the industry to ensure readiness for the broader launch of the Unified ID 2.0 integration.
Alongside these integrations Xandr has advanced its modelled and contextual solutions utilizing data science, machine learning, and contextual data to enable relevant advertising in the absence of identifiers.
Xandr has been productizing its Real Time Signals offering (RTS) which enables audience activation by using contextual signals such as hyperlocal geolocation and URL to reach audiences in identity-less environments. RTS is a differentiating, scalable way to reach our clients’ desired customers in a privacy compliant manner and Xandr recently showcased this through its work with Dentsu.
Frequency management to avoid over-exposure is a critical need for publishers and marketers. As such, Xandr has developed an inventory classification model which does not rely on cookies or device/user level identifiers. This enables Xandr to infer one brand’s ad exposure to a user based on averages in real-time and make decisions on whether or not to bid for an impression, thereby enabling platform customers to prevent consumer ad fatigue and wasted spend without reliance on user identifiers.
Xandr understands that collaboration in the industry is the best approach to solving identity. With this in mind Xandr participated in the Google FLoC trial in June and July to better understand the solution. Xandr is continuing to work across industry groups to refine and test other proposals within this, including PARAKEET.
“Xandr is focused on the development of alternative solutions for its clients. Whilst integrations are an important part of this, as is first-party data activation solutions, Xandr is also heavily focused on offering modelled and contextual solutions of its own. During this time Xandr has also been working with customers on different testing opportunities and on Xandr’s platform, buyers and sellers are now able to target, frequency cap and measure outcomes” adds Ewa Maciukiewicz, VP, Product Management, Xandr. “Whilst there is no simple solution to identity, looking ahead to 2022 Xandr is focused on scaling addressability, simplifying first-party data activation, accelerating the connection between marketers and publishers, and thinking beyond identity to drive relevant advertising in non-addressable environments.”
ABOUT XANDR
A business unit within AT&T, Xandr powers a global marketplace for premium advertising. Our data-enabled technology platform, encompassing Xandr Invest and Xandr Monetize, optimizes return on investment for both buyers and sellers. For more than 143 years, AT&T has used data and technology to inform and improve the consumer experience.
ABOUT LiveRamp
LiveRamp is the leading data connectivity platform for the safe and effective use of data. Powered by core identity resolution capabilities and an unparalleled network, LiveRamp enables companies and their partners to better connect, control, and activate data to transform customer experiences and generate more valuable business outcomes. LiveRamp’s fully interoperable and neutral infrastructure delivers end-to-end addressability for the world’s top brands, agencies, and publishers. For more information, visit www.LiveRamp.com
ABOUT EUROPEAN NETID FOUNDATION
The European netID Foundation was founded in March 2018 by Mediengruppe RTL Deutschland, ProSiebenSat.1 and United Internet with the brands WEB.DE and GMX. With an independent market solution, the foundation supports Internet offerings of all industries in implementing the new European data protection law and has created the open login standard netID for this purpose. The initiators of the foundation together reach around 50 million unique users every month and together have more than 38 million active accounts. The foundation is explicitly open for further partners and other initiatives. Further information is available at www.enid.eu.
“We are proud that our netID identifier is supported by Xandr’s end-to-end platform. This gives content providers in Europe the possibility to easily deliver personalized advertising in compliance with data protection regulations and across devices,” says Sven Bornemann, CEO of the European netID Foundation. “As well, we are very much looking forward to our partnership and warmly welcome Xandr’s Thomas Mendrina to the Publishing/Ad Sales advisory board of the European netID Foundation.”
ABOUT UNIFIED ID 2.0
Unified ID 2.0 is a next-generation identity solution that is an open-source digital framework. With initial development led by The Trade Desk, Unified ID 2.0 is the result of broad collaboration among publishers, buyers and technology providers across the industry. It serves as an alternative to third-party cookies that aims to improve consumer transparency, privacy and control, while preserving the value exchange of relevant advertising across channels and devices.
Prebid.org, the independent organization designed to ensure and promote fair and transparent marketplaces across the industry, has agreed to serve as operator of Unified ID 2.0. Prebid.org will begin this role in the second half of this year.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005390/en/
Contact information
Xandr
Kathryn Foster
kathryn.foster@xandr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 02:00:00 EEST | Press release
Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Kath Harrison, Group President, International Growth at Real Chemistry. “By bringing Spurwing into Real Chemistry,
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 21:30:00 EEST | Press release
The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stage name of Simone Privitera, an Italian multi-platinum DJ and producer who integrates artificial intelligence tools into a musical practice rooted in the contemporary electronic scene. With a career that has seen him collaborate wit
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 16:00:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 16:00:00 EEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
